Letter
Folic acid supplementation and methotrexate efficacy: Comment on articles by Schiff, Emery et al, and others
Vibeke Strand MD, Sarah L. Morgan MD, RD, Joseph E. Baggott PhD, Graciela S. Alarcón MD, MPH,
Graciela S. Alarcón MD, MPH
The University of Alabama at Birmingham
Search for more papers by this authorVibeke Strand MD, Sarah L. Morgan MD, RD, Joseph E. Baggott PhD, Graciela S. Alarcón MD, MPH,
Graciela S. Alarcón MD, MPH
The University of Alabama at Birmingham
Search for more papers by this authorFirst published: 26 March 2001
Citations: 10
43:11<2615::aid-anr38>3.0.co;2-a.fp.png)
REFERENCES
- 1 Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1870–8.
- 2 Schiff MH. Leflunomide versus methotrexate: a comparison of the European and American experience. Scand J Rheumatol 1999; 112: 31–5.
- 3 Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50.
- 4 Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43: 506–14.
- 5 Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495–505.
- 6 Cohen S, Weaver A, Schiff M, Strand V, for the Leflunomide Study Group. Two-year treatment of active rheumatoid arthritis with leflunomide compared with placebo or methotrexate [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S271.
- 7 Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655–65.
- 8 Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
- 9 Van Ede A, Laan R, Rood M, Huizinga T, van de Laar M, van Denderen J, et al. Effect of folic and folinic acid suppletion on toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double-blind, 48 week, clinical trial [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S380.
- 10 Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 9–18.
- 11 Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833–41.
- 12 Morgan SL, Baggott JE, Alarcón GS. Methotrexate in rheumatoid arthritis: folate supplementation should always be given. BioDrugs 1997; 8: 164–75.
